STOCK TITAN

Medigus Ltd. American Depositary Share - MDGS STOCK NEWS

Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.

Medigus Ltd. (NASDAQ: MDGS) is an innovative medical device company renowned for its groundbreaking endoscopic procedures and devices. The company has developed a comprehensive endoscopic system designed for the intraluminal treatment of Gastroesophageal Reflux Disease (GERD), a prevalent chronic condition in the Western world. The centerpiece of Medigus's offering is the SRS system, which integrates a miniaturized video camera, surgical stapler, and ultrasonic sights for precise alignment into a single, flexible endoscope. This unique system allows gastroenterologists and surgeons to perform endoluminal partial anterior fundoplications, thereby eliminating the need for traditional open or laparoscopic surgery, significantly advancing the clinical management of GERD.

Alongside its flagship SRS system, Medigus also designs and manufactures bespoke endoscopy systems for partner companies, leveraging its proprietary technology to meet diverse clinical needs. This dual focus on innovation in GERD treatment and custom endoscopic solutions underscores Medigus's commitment to advancing medical care through minimally invasive techniques.

Based in Israel, Medigus's recent initiatives include strategic partnerships and collaborations to expand the reach and application of their technologies. The company's financial health is bolstered by these partnerships, alongside a strong pipeline of ongoing projects aimed at enhancing patient outcomes and broadening the scope of endoscopic treatments.

For the latest updates, news, and detailed financial information, stakeholders can contact: Tali Dinar, Chief Financial Officer, at ir@medigus.com, or Michal Efraty, Investor Relations, at michal@efraty.com.

Rhea-AI Summary

Medigus Ltd. (Nasdaq:MDGS) announced that its subsidiary, Smart Repair Pro, acquired a fitness toys brand on Amazon for $4 million, with 80% financed by Medigus. The brand achieved revenues of $2.5 million in 2020, with a net profit margin of approximately 40%. Smart Repair Pro anticipates $10 million in revenues in 2021 if all acquisitions are finalized. The deal enhances its portfolio, which includes three existing brands, and aims for expansion across multiple markets including Canada and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq:MDGS) announced that its 50.1%-owned subsidiary, Smart Repair Pro, Inc., has signed agreements to acquire two brands on the Amazon Marketplace for $700,000. The deal is contingent upon standard closing conditions, including asset inspections. Smart Repair Pro aims to leverage its expertise and technology to enhance the brands' ratings and sales. Currently, the subsidiary manages three successful Amazon brands across various markets, including the U.S., Canada, and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.14%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced that the underwriter of its recent public offering exercised its option to purchase an additional 548,960 ADSs at $2.30 each. This adds approximately $9.6 million in gross proceeds, enhancing the company's financial position. The offering was conducted under an effective F-3 registration statement with the SEC. Aegis Capital Corp. served as the sole bookrunner for the offering. Further details and the final prospectus can be requested from Aegis Capital Corp.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
none
Rhea-AI Summary

Aegis Capital Corp. acted as the Sole Bookrunner for a $8.4 million Follow-On Offering for Medigus (NASDAQ:MDGS). This funding is part of Medigus' efforts in medical-related devices and innovative technologies, including products for Gastroesophageal Reflux Disease (GERD) and biological gels designed for patient protection. Medigus also explores internet technologies, emphasizing investments in ad-tech and e-commerce solutions. The offering is expected to bolster Medigus' financial position and support ongoing projects across its subsidiaries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. announced the closing of an underwritten public offering of 3,659,735 American Depositary Shares (ADSs) at $2.30 each, raising approximately $8.4 million in gross proceeds. The funds are intended for working capital and general corporate purposes. The underwriter holds a 15% option to purchase additional ADSs, potentially increasing gross proceeds to about $9.6 million. This offering is conducted under an effective registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
-
Rhea-AI Summary

Medigus Ltd. has announced a public offering of 3,659,735 American Depositary Shares (ADSs) priced at $2.30 each, aiming to raise approximately $8.4 million before expenses. The proceeds will be used for working capital and corporate purposes. The underwriter has a 15% over-allotment option, potentially increasing total gross proceeds to $9.6 million. The offering is expected to close around January 13, 2021, following standard conditions. Aegis Capital Corp. is the sole bookrunner for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.38%
Tags
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced plans for an underwritten public offering of American Depositary Shares (ADSs). The offering includes an option for underwriters to buy an additional 15% to cover over-allotments. Proceeds will be utilized for working capital and corporate purposes. The offering's completion is contingent on market conditions, with no guarantees on its size or terms. Aegis Capital Corp. is the sole bookrunner. This offering follows an effective registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) announced an agreement to acquire the intellectual property and know-how for a wireless robotic charging pad for electric vehicles. The provisional patent allows for automatic self-alignment during charging. Medigus will pay $75,000 for the rights and plans to invest an additional $150,000 in technology development. This initiative aims to expand Medigus' electric vehicle operations and will be consolidated under a new subsidiary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
none
-
Rhea-AI Summary

Medigus Ltd. (Nasdaq: MDGS) has successfully acquired a controlling interest in Smart Repair Pro, Inc. and Purex, Corp, e-commerce companies showing remarkable growth. In 2020, these companies reported a revenue increase of over 214%, reaching approximately $2.2 million compared to $0.7 million in 2019. Medigus now owns around 50.01% of each company's share capital. Smart Repair Pro plans to launch a new brand and product line, aiming to expand its sales model with a direct online store.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
Rhea-AI Summary

Medigus Ltd. (MDGS) announced that the underwriter of its public offering has fully exercised their option to purchase an additional 1,064,774 American Depositary Shares (ADSs) at $1.83 each. This brings total gross proceeds to approximately $14.93 million before expenses. The offering was made under an F-1 registration statement filed with the SEC. Aegis Capital Corp. acted as the sole bookrunner for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none

FAQ

What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?

The current stock price of Medigus Ltd. American Depositary Share (MDGS) is $2.36 as of June 11, 2024.

What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?

The market cap of Medigus Ltd. American Depositary Share (MDGS) is approximately 4.5M.

What does Medigus Ltd. specialize in?

Medigus Ltd. specializes in innovative endoscopic procedures and devices, particularly for the treatment of GERD.

What is the SRS system?

The SRS system is an endoscopic solution that combines a miniaturized camera, surgical stapler, and ultrasonic sights to treat GERD without open or laparoscopic surgery.

How does the SRS system benefit GERD patients?

The SRS system allows for a minimally invasive procedure, reducing the need for more invasive surgeries and potentially improving recovery times.

Does Medigus Ltd. collaborate with other companies?

Yes, Medigus designs and manufactures endoscopy systems for partner companies using its proprietary technologies.

Where is Medigus Ltd. based?

Medigus Ltd. is based in Israel.

Who can I contact for investor relations at Medigus?

For investor relations, you can contact Michal Efraty at michal@efraty.com.

What is the primary medical condition that Medigus's technology addresses?

Medigus's technology primarily addresses Gastroesophageal Reflux Disease (GERD).

How does the SRS system work?

The SRS system uses a flexible endoscope with a built-in camera, stapler, and ultrasonic guide to perform partial anterior fundoplication endoluminally.

What are the recent initiatives of Medigus Ltd.?

Recent initiatives include strategic partnerships and ongoing projects to enhance their technology's reach and applications.

How can I get the latest news about Medigus Ltd.?

You can get the latest news by contacting their Chief Financial Officer Tali Dinar or Investor Relations Michal Efraty, or visiting their official communications.

Medigus Ltd. American Depositary Share

Nasdaq:MDGS

MDGS Rankings

MDGS Stock Data

4.47M
28.42M
0.29%
0.22%
Medical Devices
Healthcare
Link
United States of America
Tel Aviv